Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.

Bookmark this %label%

Next-Generation Sequencing has recently been introduced to efficiently and simultaneously detect genetic variations in acute myeloid leukemia. However, its implementation in the clinical routine raises new challenges focused on the […]

» Read more

Hereditary Hemorrhagic Telangiectasia: Systemic Therapies, Guidelines, and an Evolving Standard of Care.

Bookmark this %label%

Hereditary hemorrhagic telangiectasia (HHT) management is evolving due to the emergence and development of antiangiogenic therapies to eliminate bleeding telangiectasias and achieve hemostasis. This is reflected in recent clinical recommendations […]

» Read more

How I treat venous thromboembolism in pregnancy.

Bookmark this %label%

Of 1,000 pregnant women, one to two will experience venous thromboembolism (VTE) during pregnancy or the postpartum period. Pulmonary embolism (PE) is a leading cause of maternal mortality and deep […]

» Read more

Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicentric trial.

Bookmark this %label%

Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative and useful strategy in high-risk relapsing CLL. Minimal Residual Disease (MRD) assessment at 12 months post-HSCT is predictive of relapse. […]

» Read more

Kreuth V initiative: European consensus proposals for treatment of haemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.

Bookmark this %label%

This report contains the updated consensus recommendations for optimal haemophilia care produced in 2019 by three Working Groups (WG) on behalf of European Directorate for Quality of Medicines & Healthcare […]

» Read more

Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials.

Bookmark this %label%

Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs (IMiDs) are at high venous thrombosis (VTE) risk, but data are lacking from large prospective cohorts. We present thrombosis outcome […]

» Read more

Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model.

Bookmark this %label%

Considerable inter- and intra-patient variability exist in serum activity levels of PEGasparaginase, essential for pediatric acute lymphoblastic leukemia treatment. A population pharmacokinetic (popPK) model was developed, identifying patient characteristics explaining […]

» Read more

Alternative assays to dRVVT and aPTT for lupus anticoagulant detection.

Bookmark this %label%

Lupus anticoagulants (LA) are heterogeneous antibodies and no single assay will detect every LA. Consequently, testing is commonly undertaken with both dilute Russell’s viper venom time (dRVVT) and LA-responsive activated […]

» Read more

Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease.

Bookmark this %label%

In the ISCHEMIA-CKD trial, the primary analysis showed no significant difference in the risk of death or myocardial infarction with initial angiography and revascularization plus guideline-based medical therapy (invasive strategy) […]

» Read more

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.

Bookmark this %label%

Based on the profile of genetic alterations occurring in tumor samples from selected diffuse-large-B-cell-lymphoma (DLBCL) patients, two recent whole exome sequencing studies proposed partially overlapping classification systems. Using clustering techniques […]

» Read more

Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era.

Bookmark this %label%

Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAP-kinase (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD […]

» Read more

Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis.

Bookmark this %label%

Many predictors for venous thromboembolism (VTE) and bleeding in hospitalized medical patients may exist but until now systematic reviews and assessments of the certainty of the evidence do not exist. […]

» Read more

EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.

Bookmark this %label%

Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV+ DLBCL, NOS, is an […]

» Read more

Immune Profile Differences between Chronic GvHD and Late Acute GvHD: Results of the ABLE/PBMTC 1202 Studies.

Bookmark this %label%

Human graft-versus-host disease (GvHD) biology beyond 3 months post-hematopoietic stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of Childhood Cancer (ABLE/PBMTC1202, NCT02067832) study evaluated the immune […]

» Read more

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.

Bookmark this %label%

Mast cell leukemia (MCL), the leukemic manifestation of systemic mastocytosis (SM), is characterized by leukemic expansion of immature mast cells (MCs) in the bone marrow (BM) and other internal organs; […]

» Read more

Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.

Bookmark this %label%

In the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guideline, the definition of hypertension was lowered from a blood pressure (BP) of greater than or equal to 140/90 […]

» Read more

Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma.

Bookmark this %label%

Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective drugs. The recent development of chimeric antigen receptor (CAR)-T cell therapy has shown impressive results […]

» Read more

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.

Bookmark this %label%

Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend monitoring for measurable residual disease every 3 months for […]

» Read more

Identifying and Treating Refractory ITP: Difficulty in Diagnosis and Role of Combination Treatment.

Bookmark this %label%

Immune Thrombocytopenia (ITP) is the commonest acquired thrombocytopenia after chemotherapy-induced thrombocytopenia. Existing guidelines describe the management and treatment of most patients who overall do well, even if they present with […]

» Read more

Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial.

Bookmark this %label%

Abstract: Excessive bleeding is a common complication of cardiac surgery. An important cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which guidelines recommend fibrinogen replacement with cryoprecipitate […]

» Read more

Preventing Infectious Complications When Treating Non-Malignant Immune-Mediated Hematologic Disorders.

Bookmark this %label%

Abstract: Immunosuppressants, targeted antibody therapies, and surgical splenectomy are amongst the treatment choices for immune-mediated non-malignant hematologic disorders, with infection being the most common non-hematological adverse event from these therapies. […]

» Read more
1 2